Delivery Order SPE2DB22D1017-SPE2DB25FG8RX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,687.48 to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 14, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. ProQuad is a combination vaccine used for immunization against measles, mumps, rubella, and varicella, representing the type of critical medical supply that...
- The Defense Logistics Agency awarded a $1,670.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 15, 2025. This is a non-set-aside, competitively awarded contract executed on July 25, 2025, with performance at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $3,341.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on July 21, 2025, with an ultimate completion date of August 11, 2025. This competitive award, issued without set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. ProQuad is a combination vaccine protecting...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $8,354.50 under a firm fixed-price contract. The award was made on July 25, 2025, with an ultimate completion date of August 15, 2025. This is a non-set-aside, competitively awarded delivery order, with performance to take place at the contractor's Corporate Office location in Conshohocken, Pennsylvania. ProQuad is a combination vaccine used for immunization against measles,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,308.68 to AmerisourceBergen Drug Corp for ProQuad vials on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price delivery order represents a competitively awarded, non-set-aside contract with performance to be completed at the contractor's Conshohocken, Pennsylvania facility. ProQuad is a combination vaccine for measles, mumps, rubella, and varicella, indicating this delivery supports...
- The Defense Logistics Agency awarded a $16.87K delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with performance in Conshohocken, Pennsylvania and an ultimate completion date of August 15, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation. ProQuad is a combination vaccine for measles, mumps, rubella, and varicella, which aligns with AmerisourceBergen's established role as a critical federal pharmaceutical and medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,670.90 to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 18, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of ProQuad vials valued at $5,426.92, with an ultimate completion date of August 14, 2025. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award was made through open competition with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $3,374.88, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed through AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. ProQuad is a combination vaccine providing immunization against measles, mumps, rubella, and varicella, supporting...
- The Defense Logistics Agency awarded a $16,543.30 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, a combination vaccine product, with a completion date of August 21, 2025. This competitive award (no set-aside used) was issued under a firm fixed-price structure and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8RXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,686.44 to AmerisourceBergen Drug Corp for ProQuad vials on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order, which is not set-aside, will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical vendor, will supply ProQuad, a combination vaccine used for immunization against measles, mumps, rubella, and varicella. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The contract reflects AmerisourceBergen Drug Corp's established capability to meet federal procurement requirements through open competition and its role as a primary pharmaceutical vendor for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 7/31/25 |